Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment FRIENDSWOOD, Texas, Sept. 24,